FLUOROPHARMA MEDICAL, INC. (FPMI) - Description of business

Company Description

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with primary applications in the area of cardiology. It develops positron emission tomography imaging agents for the detection and assessment of acute and chronic forms of coronary artery disease (CAD). The company?s clinical-stage molecular imaging pharmaceutical product candidates include BFPET, which is in Phase I trial used for the detection of ischemic and infarcted tissue within the myocardium in patients with suspected or proven chronic CAD; and CardioPET that is in Phase II development stage for the assessment of myocardial metabolism.